DnB Asset Management
NTLA icon

DnB Asset Management’s Intellia Therapeutics NTLA Stock Holding History

DnB Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,586
Closed -$127K – 754
2025
Q2 		$127K Buy
+13,586
New +$112K ﹤0.01% 705
2024
Q4 		– Sell
-43,962
Closed -$903K – 743
2024
Q3 		$903K Buy
+43,962
New +$1.01M ﹤0.01% 635

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DnB Asset Management's NTLA Position: Q3 2025 in Review

DnB Asset Management sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 13,586 shares — an estimated $127K sold.

DnB Asset Management first reported a position in NTLA in Q3 2024 and held it in 2 quarters. The position peaked at $903K in Q3 2024. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • DnB Asset Management reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • DnB Asset Management sold 13,586 Intellia Therapeutics shares in Q3 2025, an estimated $127K.
  • DnB Asset Management first reported a position in Intellia Therapeutics in Q3 2024 and held it in 2 quarters.
  • DnB Asset Management's Intellia Therapeutics position peaked at $903K in Q3 2024.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on DnB Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.